Human embryonic stem (HES) cells can give rise to cardiomyocytes in vitro. However whether undifferentiated HES cells also feature a myocardial regenerative capacity after in vivo engraftment has not been established yet.
Introduction
Heart failure is becoming a predominant disease and a leading cause of death in most of developed countries. Regardless of the origin of myocardial failure (i.e, ischemic or genetic), the clinical symptoms result mainly from the death of cardiomyocytes replaced by a fibrotic and non contractile tissue. Pharmacological approaches to cure or relieve heart failure have been facing limitations. Because of a limited regeneration capability of the heart [1] and a shortage in donors for heart transplantation, an external source of cells has been envisioned as a therapeutic solution to bring a gain in function to diseased myocardium. For the last few years, hematopoietic stem cells had raised many hopes as a potential autologous cell source to repair diseased myocardium. However, the enthusiasm generated by the early non-controlled phase I studies has been dampened by the more recent recognition that out of four randomised controlled trials entailing intracoronary infusions of bone marrow-derived cells shortly after myocardial infarction, three failed to meet their primary end point, i.e., an improvement in left ventricular ejection fraction [2] [3] [4] [5] . Combined with basic studies disproving the cardiogenic potential of these cells [6] [7] , the outcome of these trials demonstrates that these cells do not really regenerate the diseased myocardium and it is unlikely that their paracrine effects may be sufficient for restoring function of extensively scarred myocardium [8] . The same limitations apply to skeletal myoblasts [9] .Thus, these findings call for another stem cell source to achieve myocardial regeneration. Among various other cell types, embryonic stem (ES) cells [10] [11] [12] or ES cell-derived cardiomyocytes [13, 14] have turned out to be the most promising for replacing scar fibrosis by new contractile elements. However, the number of cells required to regenerate a post-infarcted human myocardium (i.e., several hundreds of million) is too high to be reasonably achieved by in vitro engineering of ES cell-derived cardiomyocytes. For the last few years, we and others have shown that proliferative mouse ES cells engrafted in a diseased myocardium further differentiate into functional cardiomyocytes HAL author manuscript inserm-00149211, version 1 following in-vitro commitment using the cardiogenic morphogen BMP2 [10] [11] [12] . Cardiacspecified cells then complete their differentiation in response to the local cues present in the scar and do not generate any kind of tumors. Thus, although Human ES cells do not share with mouse ES cells the same molecular mechanisms of self-renewal or capabilities of spontaneous differentiation [15] , we designed this study to assess whether Human ES cells could be specified toward a cardiac lineage in vitro and subsequently differentiate into cardiomyocytes in situ following their transplantation in infarcted myocardium.
Herein, we bring the proof of concept that Human ES cells can also be directed toward a cardiogenic fate using the morphogen BMP2. Furthermore, the cells do differentiate into cardiomyocytes following engraftment into the myocardial scar without any sign of hyperproliferation. These data open the path for the use of early cardiac progenitors, which retain the capability to proliferate and repopulate the postinfarction scar.
Materials and Methods

Real-Time Quantitative PCR by SYBR Green Detection
RNA was extracted from HES cells or slices of rat myocardium using a Quiagen kit. One μg of RNA was reverse-transcribed using the Mu-MLV reverse transcriptase (Invitrogen, Cergy, France) and oligo (16) Fluorescence was measured through the slow heating phase. Melting curves were used to determine the specificity of PCR products, which were confirmed using conventional gel electrophoresis. Data were analysed according to Pfafll et al [16] . Primers specific for human genes are described in table 1.
Culture and cardiac commitment of Human Embryonic stem cells
HAL author manuscript inserm-00149211, version 1 HUES-1 and I6 cell lines were cultured on Mouse Embryonic Fibroblasts (MEF) prepared from E14 mouse embryos using KO-DMEM medium supplemented with mercaptoethanol, glutamine, non essential amino acids, 15% KOSR and 10 or 5 ng/ml FGF2 respectively.
Medium was changed every day. Cell colonies were dissociated into single cells or cell clusters every 4-5 days using trypsin (HUES-1) or collagenase (I6), respectively. A similar enzymatic digestion was used prior to cell transplantation in infarcted rats.
HES cells were treated for 48 hrs with 10 ng/ml BMP2 in the presence or absence of 1 μM SU5402, a FGF receptor inhibitor, in low KOSR (5%) containing KO-DMEM. Embryoïd bodies were generated after trypsinisation (HUES-1) or collagenase (I6) dissociation of HES cell colonies and cell aggregation in low attachment dishes (Nunc) in DMEM, 10% foetal calf serum.
Myocardial infarction model
Myocardial infarction was induced in female Wistar (mean weight of 250 g ) by ligation of the left coronary artery. Rats were operated on under general anaesthesia with isoflurane ( Baxter), 3% at induction and 2% for maintenance. After tracheal intubation, mechanical ventilation ( Alphalab, Minerve ) was set at a rate of 70/min and with an 0.2 ml average insufflate volume. Analgesia was performed with a 10mg/kg subcutaneous injection of ketoprofen (Merial).
The heart was exposed through a left thoracotomy and the left coronary artery was permanently snared between the pulmonary artery trunk and the left atrial appendage.
Rats randomization and myocardial cell injection
On the 15 th day following infarction, the rats were reoperated on by median sternotomy and randomized to receive injections of BMP2-treated HUES-1 cells (3x10 6 HUES-1 cells, n= 11 rats) in suspension of single cells, BMP2-treated I6 ES cells (3 10 6 I6 cells, n= 11 rats) in suspension of small cell clusters or control medium (n= 9 rats). Additional animals (n= 5 rats) received in-scar injections of 3 10 6 HUES-1 cells that had been exposed to both BMP2 and SU5402. We selected HUES-1 cell line for the latter experimental situation since this is the one which is not already committed to the mesoderm. One rat of each group (HUES-1 celland I6 cell-transplanted) died within 48 hrs after cell injection.
Immunosuppressive therapy, consisting in one daily 10mg/kg subcutaneous shot of cyclosporine A, was started on the same day and continued until sacrifice.
Histopathology
Myocardial sections were stained with eosin and hematoxylin using a standard protocol.
Two months after myocardial injection, rats were euthanized after general anaesthesia.
Transverse-cut rat hearts were immediately fixed in OTC (Tissutec) and frozen at -180°C
nitrogen. Eight μm sections were cut on an ultramicrotome (LM 1850,Leica).
Potential tumor growth was assessed with 8 μm standardized sections stained with hematoxylin and eosin.
Immunofluorescence of myocardial cryosections were performed after paraformaldhehyde fixation and permeabilisation using Triton X-100 with an anti-human ventricular β myosin heavy chain (MHC) (Chemicon) , anti-human lamin A/C (Novacastra) anti-atrial natriuretic peptide (ANP, Abgent) and anti-Connexin 43 (Cx43) (SIGMA) antibodies. The proteins were revealed using alexa-conjugated antibodies. Sections were observed in confocal microscopy (ZEISS LSM-510 meta).
In addition, a whole-body autopsy of each transplanted rat, including brain, lungs, liver, spleen, pancreas, kidneys, periaortic lymph nodes, thymus, spine and ovaries, was systematically performed for the detection of a tumor.
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Results
Phenotype of undifferentiated I6 and HUES-1 cell lines
We used both HUES-1 and I6 HES cell lines to test their cardiogenic potential in vitro and in vivo. Indeed, a real-time PCR amplification of a few mesodermal and cardiac genes in both cell lines showed that the I6 cell line featured a higher basal expression of both mesodermal (Tbx6, SRF, Mesp1, brachyury) and early cardiac (Isl1, Mef2c,Tbx20) genes. GATA4 was weakly expressed in I6 but not in HUES-1 cells. Nkx2.5 was barely detected in either I6 or HUES-1 cell lines. Oct-4 level was not significantly different between both cell lines (Fig. 1 ).
Cardiac commitment of HES cells
Both I6 and HUES-1 Human ES cells were treated for 48hrs with 10 ng/ml human recombinant BMP2. Gene induction was tested using real time Q-PCR. To test whether BMP2-induced HES cell commitment was translated into a process of cardiac differentiation and to envision the differentiation scenario that might take place in vivo, control or BMP2-challenged HUES-1 cells were allowed to aggregate to form embryoid bodies (EBs). Gene expression was then monitored in day 2 and day 5 EBs. BMP2 effect was observed at day 2 (i.e. two fold induction in gene expression) and became prominent at day 5
( Fig. 2B) . At that stage of development, expression of both mesodermal and cardiac genes was dramatically increased by 3 to 10 folds (Fig. 2) . In contrast, Oct-4 was downregulated and almost absent in EBs generated from BMP2-treated ES cells. Similar results were obtained using I6 cell line.
Engraftment of cardiac committed cells in post-infarcted rat heart
Two months after coronary artery ligation, Human α-actin mRNAs were identified in transplanted hearts but not in those injected with the control medium (Fig. 3) . In contrast, we could not detect any mRNA encoding Oct-4, Pax6 (an early ectodermal marker) or α-foeto protein, an early endodermal marker (data not shown).
Immunostaining with an anti-ANP and anti-human lamin antibodies revealed the presence of lamin-positive human ES cell derived-cardiomyocytes ( (Fig. 4C) , respectively. Careful examination of these sections further indicated that these cardiomyocytes were still at a foetal stage demonstrated by a shorter sarcomeric length (1.6±0.1μm) compared to 2 ±0.1μm in adult rat (Fig. 4D) Eosin-hematoxylin stained sections did not show any sign of inflammation or cell hyperproliferation two months posttransplantation (Fig. 5) . Likewise, whole-body autopsies failed to disclose any tumor in peripheral organs.
Discussion
Our study reveals that HES cells are capable to differentiate into cardiomyocytes without formation of teratomas after commitment toward a cardiac lineage using the cardiogenic factor BMP2. While BMP2 was shown to improve late cardiac differentiation of already differentiating cells [17] , our study reports the strong instructive action of the morphogen on undifferentiated HES cells.
BMP2 is a potent mesodermal and cardiogenic instructor when used at low concentration. Its cardiogenic potential is a well conserved property throughout the evolution. Dpp, the drosophila homolog of BMP2, favours formation of the mesoderm including the heart [18] .
Similar effects have been observed in zebrafish [19] , Xenopus [20, 21] and chicken [22] . Our data obtained in two separate cell lines uncovered that BMP2 function is conserved in human species. While I6 cells were more prone to give rise to a mesodermal lineage (Fig.1) , maximal BMP2 response was not significantly different from the one observed with HUES-1 cells although maximal extent of gene expression was higher in I6 than in HUES-1 cells. Used alone, in a defined (KOSR) medium, BMP2 effect was weak while its instructive action was dramatically enhanced by addition of the FGF receptor inhibitor, SU5402. Indeed, Human ES cells are grown on feeder cells which secrete many factors including FGF2 which is known to antagonize the BMP2 signaling pathway. SU5402 could act through at least two mechanisms to unmask the BMP2 transcriptional effect. First, FGF2 phosphorylates smad2/3, thereby preventing the BMP2 signaling co-factor from translocating into the nucleus and thus to exert its transcriptional action [23] . Second, FGF2 is also known to act as a paracrine factor on both MEF and HES cells to regulate expression of Cerberus, a nodal and BMP antagonist enriched in HES cells [24] . Finally, it might be that SU5402 blocks self-renewal of cells and favours non-specific differentiation which is further directed to the mesoderm by BMP2. By blocking all or either one of these pathways, the FGF inhibitor is required to unravel the BMP2 transcriptional response of HES cells.
In keeping with previous observations made in hearts transplanted with mouse [10, 11, 25] , and human [26] ES cells, no hyperproliferation (teratoma) was observed in any of the rats injected with cardiac-committed HES cells. As intramyocardial injections in a beating heart are also known to cause leakage of a substantial proportion of cells [27] , it is also noteworthy that we failed to document any extra-cardiac tumor. In fact, it was known for a long time that grafts of embryonic tissue also loose the capacity to form tumors very early after differentiation [28] when they acquire control of their proliferation by extracellular signal regulated kinases. It is thus not surprising that a similar scenario takes place after cardiac commitment of HES cells.
As such, our findings are not in contradiction with the previous observation [11] that injection of HES cells into a normal immunocompetent myocardium results in teratoma formation since the latter results primarily suggest that such an environment is unlikely to provide enough cardiogenic factors required for differentiation of ES cells. Of note, the rather reassuring safety data yielded by our experiments were obtained despite the lack of pretransplantation sorting targeted at eliminating non specified cells. This suggests that the environment of the diseased myocardium (i.e., scar) enriched in growth factors is sufficient to drive primed ES cells toward a cardiac fate [25] . In a clinical perspective, however, such a selection step remains a major goal.
So far, two studies have assessed the effects of intramyocardial transplantation of HES cells. Both have entailed the use of embryoid body-derived cardiomyocytes into either normal myocardium [26] or acutely infarcted myocardium [29] . To make the protocol more clinically relevant, we selected a delayed timing of in-scar transplantation that tends to mimick the clinical scenario of heart failure and injected cardiac-specified but not yet fully differentiated monolayer-cultured cardiac progenitors. Altogether, the engraftment patterns seen after 2 Alternatively, the paracrine environment of the infarction scar may not provide the factors (some FGFs, Neuregulin, retinoic acid, BMP10…) [30] or signals taking place in embryogenesis to ensure a full differentiation process.
Another interesting observation is that I6 cells gave rise to larger engraftment areas than HUES-1 cells. Although both cell lines respond with the same efficiency to BMP2, I6 cells feature a higher basal expression of mesodermal cardiac genes (Fig 1) . This indicates that the cell line is already committed to the mesoderm, which is likely to account for the better cardiogenic potential in vivo. Of note, HUES-1 cells pretreated with BMP2 together with SU5402 also featured a better engraftment than HUES-1 challenged by BMP2 alone.
This further emphasizes that the stage of specification is crucial to ensure a proper differentiation of ES cells in situ. The finding that the rates of scar repopulation by the grafted cells was overall low probably reflects a combination of initially insufficient cell dosing, extracardiac cell leakage at the time of injections and possible death of retained cells. Clearly, optimisation of the functional benefits of ES cells transplantation will require that each of these issues be thoughtfully addressed.
Finally, and in contrast to what has been reported in our previous studies using mouse ES cells [10, 31] , we could not detect Cx43 mRNA or protein in HES cell-derived cardiomyocytes. HES-cell derived differentiated cardiomyocytes [13] did not either express Cx43 when transplanted in injured left ventricle while they did express it when co-cultured with neonatal rat cardiomyocytes [32] . 
